No. | Primary tumor | Moment of scan | Site | (Median) SUVmax | Range | |
---|---|---|---|---|---|---|
PSMA | FDG | |||||
1 | 2008 | 2017 | No pathological uptake | – | – | |
2018 | Leptomeningeal/drop metastases Th10 | 2.66 | 2.66 | |||
2018 | No pathological uptake | – | – | |||
2 | 2008 | 2017 | Lungs | 5.02 | 4.46–5.35 | |
Th4 | 2.94 | 2.94 | ||||
2017 | Lungs | 5.45 | 4.54–7.99 | |||
Th4 | 2.79 | 2.79 | ||||
2017 | Left cervical lymph nodes | 3.33 | 3.04–3.61 | |||
Lungs | 8.03 | 7.65–9.40 | ||||
Liver | 7.18 | 5.84–8.52 | ||||
2017 | Left cervical lymph nodes | 3.82 | 2.90–4.73 | |||
Decrease in lungs | 8.67 | 6.56–10.56 | ||||
Decrease in liver | 6.01 | 6.01 | ||||
2018 | Unchanged left cervical lymph nodes | 4.20 | 4.00–2.40 | |||
Increase in lungs | 5.44 | 5.07–8.16 | ||||
3 | 2013 | 2016 | Lungs | 1.85 | 0.93–2.66 | |
2017 | Lungs | 3.61 | 1.31–4.66 | |||
2018 | Recurrence/metastasis central compartment | 3.61 | 3.61 | |||
Lungs | 3.21 | 2.27–4.89 | ||||
4 | 2010 | 2016 | Residual thyroid bed | 4.55 | 4.55 | |
Lungs | 4.44 | 2.51–7.51 | ||||
Mediastinal/hilar lymph nodes | 15.31 | 11.03–26.24 | ||||
Lymph node m. pectoralis | 1.93 | 1.93 | ||||
Lymph node parasternal | 1.37 | 1.37 | ||||
2016 | Residual thyroid bed | 1.38 | 1.38 | |||
Lungs | 1.54 | 1.28–1.79 | ||||
Mediastinal/hilar lymph nodes | 2.42 | 2.26–6.97 | ||||
Lymph node m. pectoralis | 0.85 | 0.85 | ||||
5 | 1996 | 2016 | Right cervical lymph nodes | 4.35 | 3.56–5.13 | |
Lungs | 1.73 | 1.44–3.39 | ||||
2017 | Right cervical lymph nodes | 3.35 | 2.12–8.36 | |||
Retropharyngeal | 5.43 | 5.43 | ||||
Lungs | 2.85 | 1.83–3.76 | ||||
2017 | Right cervical lymph nodes | 3.99 | 3.57–4.50 | |||
Retropharyngeal | 5.82 | 5.82 | ||||
Lungs | 3.44 | 2.49–5.49 |